SDC1 and Miyoshi myopathy: Taken together, these results show that the drug screening pipeline is robust and our ex vivo culture set‐up could preserve the viability of patient‐derived MM cells (CD138+) when stimulation was introduced for 24–48 h prior to the drug screening analyses.